News

A newly-developed machine learning system may help act as an alert system for potential adverse effects from drug-drug interactions.
 
Top news of the day from across the health care landscape.
 
An analysis presented at the American Heart Association Annual Scientific Sessions showed that evolocumab (Repatha, Amgen) lowered the risk of cardiovascular events in patients who have recently had a heart attack.
FDA approval
Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.
cvMOBIUS will examine lipid management and the effectiveness of evolocumab (Repatha, Amgen) on cardiovascular outcomes.
Implementing more aggressive treatment plans from the American Heart Association’s 2017 guide were seen as more cost-effective over 10 years.
Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss the goals and importance of his company, Stack, during the NASP Annual Meeting in Washington, DC.
FDA Approves Treatment for Sickle Cell Disease
Crizanlizumab-tmca (Adakveo, Novartis) is approved to reduce the frequency of vaso-occlusive crises in patients aged 16 years and older with sickle cell disease.
 
Top news of the day from across the health care landscape.
Cefiderocol (Fetroja, Shionogi) is indicated for adults with complicated urinary tract infections, including kidney infections caused by Gram-negative pathogens, who have limited or no alternative treatment options.
 
Cenobamate is an investigational antiepileptic drug that has shown broad spectrum anticonvulsant activity in preclinical studies and seizure models.
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for the treatment of mantle cell lymphoma in adults who have received at least 1 prior therapy.
 
Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how vertical integration might affect biosimilar availability in specialty pharmacy during the NASP Annual Meeting in Washington, DC.
ECRI Institute, Institute for Safe Medication Practice Enter into Affiliation Agreement
According to the affiliation agreement, the Institute for Safe Medication Practices will be an ECRI Institute subsidiary when the transaction closes in January, 2020.
+ Load More